Elizabeth Crago1, Kelly Kerris, Chien-Wen J Kuo, Paula Sherwood, Marilyn Hravnak, David Crippen, Michael Horowitz. 1. Elizabeth Crago is a research assistant professor and Kelly Kerris is an acute care clinical nurse specialist currently working on her post-master's ACNP certificate at the University of Pittsburgh, School of Nursing, Pittsburgh, Pennsylvania. Chien-Wen J. Kuo is a biostatistician at Columbia University, New York, New York. Paula Sherwood is a professor and the vice chair for research and Marilyn Hravnak is a professor in the Acute/Tertiary Care Department at the University of Pittsburgh, School of Nursing. David Crippen is a critical care medicine physician and codirector of the neurovascular intensive care unit at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Michael Horowitz is a neurological surgeon and the codirector of the Pennsylvania Brain and Spine Institute, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Cardiac abnormalities attributed to adrenergic surge are common after aneurysmal subarachnoid hemorrhage. Prescribed medications that block adrenergic stimulation may suppress the onset of cardiopulmonary compromise in patients after aneurysmal subarachnoid hemorrhage. OBJECTIVES: To compare the incidence of early cardiac complications between patients who reported prescribed use of β-blockers and/or angiotensin-converting enzyme inhibitors before aneurysmal subarachnoid hemorrhage and patients who did not. METHODS: A retrospective review of 254 adult patients after acute aneurysmal subarachnoid hemorrhage who were enrolled in an existing R01 study. Demographic data and history were obtained from patients'/proxies' reports and charts. Cardiac enzyme levels, 12-lead electrocardiograms, and chest radiographs were obtained on admission. Holter monitoring and echocardiograms were completed as a part of the R01 study. RESULTS: Patients reporting prescribed use of angiotensin-converting enzyme inhibitors or β-blockers before aneurysmal subarachnoid hemorrhage had more ventricular and supraventricular ectopy on a Holter report than did patients who did not (P < .05). When age, race, sex, and injury (Fisher grade) were controlled for, patients reporting use of β-blockers were 8 times more likely than others to have occasional to frequent ventricular ectopy (P = .02). CONCLUSION: No concrete evidence was found that exposure to adrenergic blockade before aneurysmal subarachnoid hemorrhage provides protection from neurocardiac injury.
BACKGROUND:Cardiac abnormalities attributed to adrenergic surge are common after aneurysmal subarachnoid hemorrhage. Prescribed medications that block adrenergic stimulation may suppress the onset of cardiopulmonary compromise in patients after aneurysmal subarachnoid hemorrhage. OBJECTIVES: To compare the incidence of early cardiac complications between patients who reported prescribed use of β-blockers and/or angiotensin-converting enzyme inhibitors before aneurysmal subarachnoid hemorrhage and patients who did not. METHODS: A retrospective review of 254 adult patients after acute aneurysmal subarachnoid hemorrhage who were enrolled in an existing R01 study. Demographic data and history were obtained from patients'/proxies' reports and charts. Cardiac enzyme levels, 12-lead electrocardiograms, and chest radiographs were obtained on admission. Holter monitoring and echocardiograms were completed as a part of the R01 study. RESULTS:Patients reporting prescribed use of angiotensin-converting enzyme inhibitors or β-blockers before aneurysmal subarachnoid hemorrhage had more ventricular and supraventricular ectopy on a Holter report than did patients who did not (P < .05). When age, race, sex, and injury (Fisher grade) were controlled for, patients reporting use of β-blockers were 8 times more likely than others to have occasional to frequent ventricular ectopy (P = .02). CONCLUSION: No concrete evidence was found that exposure to adrenergic blockade before aneurysmal subarachnoid hemorrhage provides protection from neurocardiac injury.
Authors: Richard E Temes; Elena Tessitore; J Michael Schmidt; Andrew M Naidech; Andres Fernandez; Noeleen D Ostapkovich; Jennifer A Frontera; Katja E Wartenberg; Marco R Di Tullio; Neeraj Badjatia; E Sander Connolly; Stephan A Mayer; Augusto Parra Journal: Neurocrit Care Date: 2010-12 Impact factor: 3.210
Authors: Marilyn Hravnak; J Michael Frangiskakis; Elizabeth A Crago; Yuefang Chang; Masaki Tanabe; John Gorcsan; Michael B Horowitz Journal: Stroke Date: 2009-08-27 Impact factor: 7.914
Authors: Martina Teichert; Peter A G M de Smet; Albert Hofman; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Masaki Tanabe; Elizabeth A Crago; Matthew S Suffoletto; Marilyn Hravnak; J Michael Frangiskakis; Amin B Kassam; Michael B Horowitz; John Gorcsan Journal: Am J Cardiol Date: 2008-10-01 Impact factor: 2.778